Flavone acetic acid: a nonlinear pharmacokinetic model. 1988

A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
Clinical Pharmacology Unit (UA147 CNRS and U140 INSERM), Institut Gustave-Roussy, Villejuif, France.

Flavone acetic acid pharmacokinetics were studied in 31 patients in a phase I clinical trial. The drug was given by i.v. infusions over 1, 1.5, 3, and 6 h at doses ranging from 0.5 to 6.4 g/m2. The pharmacokinetic parameters were determined according to a nonlinear model including Michaelis-Menten-type kinetics. The mean elimination half-life is 4.8 h and the mean volume of distribution of the central compartment, 7.61. Our model predicted a maximal tolerated dose (MTD) of 11.1 g/m2 on the basis of the "therapeutic window" concept, very close to the clinically observed MTD of 10 g/m2. This model is also operational when different protocols of inoculation are considered, such as a divided-dose schedule vs a unique infusion, and indicates that, at the MTD, injections should be made every 72 h to avoid drug accumulation.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000465 Algorithms A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. Algorithm

Related Publications

A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
December 1987, Cancer research,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
January 1991, Journal of the National Cancer Institute,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
June 1986, Cancer research,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
January 1992, Cancer chemotherapy and pharmacology,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
October 1990, Cancer research,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
November 1989, British journal of cancer,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
September 1989, European journal of cancer & clinical oncology,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
January 1989, Bulletin du cancer,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
January 1990, Cancer chemotherapy and pharmacology,
A Gouyette, and D J Kerr, and S B Kaye, and A Setanoians, and J Cassidy, and C Bradley, and G Forrest, and M Soukop
January 1990, Anticancer research,
Copied contents to your clipboard!